These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

618 related items for PubMed ID: 17020653

  • 41. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy.
    Roldán V, Marín F, Gimeno JR, Ruiz-Espejo F, González J, Feliu E, García-Honrubia A, Saura D, de la Morena G, Valdés M, Vicente V.
    Am Heart J; 2008 Jul; 156(1):85-91. PubMed ID: 18585501
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis.
    Mühl D, Nagy B, Woth G, Falusi B, Bogár L, Weber G, Lantos J.
    J Crit Care; 2011 Dec; 26(6):550-5. PubMed ID: 21530151
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Matrix metalloproteinase-2 and -9 levels in obese patients.
    Derosa G, Ferrari I, D'Angelo A, Tinelli C, Salvadeo SA, Ciccarelli L, Piccinni MN, Gravina A, Ramondetti F, Maffioli P, Cicero AF.
    Endothelium; 2008 Dec; 15(4):219-24. PubMed ID: 18663625
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Imbalance between matrix metalloproteinases (MMP-9 and MMP-2) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in acute respiratory distress syndrome patients.
    Lanchou J, Corbel M, Tanguy M, Germain N, Boichot E, Theret N, Clement B, Lagente V, Malledant Y.
    Crit Care Med; 2003 Feb; 31(2):536-42. PubMed ID: 12576963
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Plasma MMP-2-TIMP-2 complex levels measured during follow-up predict a risk of relapse in patients with malignant lymphoma.
    Pennanen H, Kuittinen O, Turpeenniemi-Hujanen T.
    Eur J Haematol; 2008 Jan; 80(1):46-54. PubMed ID: 18028436
    [Abstract] [Full Text] [Related]

  • 55. Serum levels of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 in subacute sclerosing panencephalitis.
    Ichiyama T, Siba P, Suarkia D, Takasu T, Miki K, Kira R, Kusuhara K, Hara T, Toyama J, Furukawa S.
    J Neurol Sci; 2007 Jan 15; 252(1):45-8. PubMed ID: 17118404
    [Abstract] [Full Text] [Related]

  • 56. Reduced levels of MMP-2 and TIMP-1 in dyssegmental dysplasia.
    Uchide K, Ueno H, Takizawa N, Okada Y.
    J Bone Miner Res; 2003 Feb 15; 18(2):381-2. PubMed ID: 12568417
    [Abstract] [Full Text] [Related]

  • 57. Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis.
    Comabella M, Río J, Espejo C, Ruiz de Villa M, Al-Zayat H, Nos C, Deisenhammer F, Baranzini SE, Nonell L, López C, Julià E, Oksenberg JR, Montalban X.
    Clin Immunol; 2009 Feb 15; 130(2):145-50. PubMed ID: 18945642
    [Abstract] [Full Text] [Related]

  • 58. Urokinase-type plasminogen activator and metalloproteinase-2 are independently related to the carotid atherosclerosis in haemodialysis patients.
    Pawlak K, Pawlak D, Myśliwiec M.
    Thromb Res; 2008 Feb 15; 121(4):543-8. PubMed ID: 17706748
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.